

US0D1084128S

(12)

United States Design Patent

Hockmuller et al.

(10) Patent No.: US D1,084,128 S

(45) Date of Patent: ** Jul. 15, 2025

(54) LABEL

(71) Applicant: Eli Lilly and Company, Indianapolis, IN (US)

(72) Inventors: Frank N. Hockmuller, Noblesville, IN (US); Julia Freitag McGreevy, Jersey City, NJ (US); Ross Stephen Merkel, Fishers, IN (US); Joseph Vito Primiani, Astoria, NY (US); NatalieAnn DeWitt Rich, New York, NY (US); J Geoffrey Swope, Indianapolis, IN (US)

(73) Assignee: ELI LILLY AND COMPANY, Indianapolis, IN (US)

(**) Term: 15 Years

(21) Appl. No.: 29/915,908

(22) Filed: Nov. 6, 2023

(51) LOC (15) Cl. 19-08

(52) U.S. Cl. D20/27; D20/22

(58) Field of Classification Search USPC D2/717, 840, 853, 854, 891, 895, 999; D5/63, 64, 65, 66, 99; D9/415, 418, 434, D9/438, 456, 457, 499, 643, 702, 715, D9/719, 722, 752; D19/1, 2, 3, 4, 5, 6, D19/7, 8, 9, 10, 11, 12; D20/10, 11, 18, D20/22, 23, 24, 25, 26, 27, 28, 29, 34, D20/40, 49, 99; D24/224, 225, 226, 231 CPC G09F 3/00; G09F 1/02; G09F 1/04; G09F 3/005; G09F 3/02; G09F 2003/0201; G09F 2003/0202; G09F 2003/0208; G09F 2003/0214; G09F 2003/023; G09F 2003/0257; G09F 2003/0264; G09F (Continued)

(56) References Cited

U.S. PATENT DOCUMENTS

D432,245 S * 10/2000 Stevens D24/224

D435,662 S * 12/2000 Stevens D24/224

(Continued)

FOREIGN PATENT DOCUMENTS

EM 015003050-0001 11/2022

GB 6243007 11/2022

(Continued)

OTHER PUBLICATIONS

“How to Use the Trulicity Pen for Type 2 Diabetes | Trulicity (dulaglutide),” www.trulicity.com/how-to-use. Accessed Jun. 10, 2022.

(Continued)

Primary Examiner — Catherine Ho

(74) Attorney, Agent, or Firm — M. Daniel Spillman

(57) CLAIM

The ornamental design for a label, as shown and described.

DESCRIPTION


The patent or application file contains at least one drawing executed in color. Copies of this patent or application with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 is a front view of a first embodiment of a label; FIG. 2 is a front view of a second embodiment of a label; FIG. 3 is a front view of a third embodiment of a label; FIG. 4 is a front view of a fourth embodiment of a label; FIG. 5 is a front view of a fifth embodiment of a label; FIG. 6 is a front view of a sixth embodiment of a label; FIG. 7 is a view of a seventh embodiment of a label; and, FIG. 8 is a view of an eighth embodiment of a label.

The greyscale shading in the Figures represents a contrast in appearance.

1 Claim, 8 Drawing Sheets

(6 of 8 Drawing Sheet(s) Filed in Color)



(58) **Field of Classification Search**
CPC 2003/0272; G09F 2003/0276; G09F
2003/028; G09F 3/0288; G09F 3/0291;
G09F 3/0297; G09F 3/03
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

D435,663 S * 12/2000 Stevens D24/224
D435,664 S * 12/2000 Stevens D24/224
D436,182 S * 1/2001 Stevens D24/224
D436,183 S * 1/2001 Stevens D24/224
D588,200 S * 3/2009 Langan D20/27
D593,613 S * 6/2009 Langan D20/27
D595,361 S * 6/2009 Langan D20/22
D597,608 S * 8/2009 Langan D20/27
D602,534 S * 10/2009 Langan D20/27
D605,228 S * 12/2009 Langan D20/27
D605,229 S * 12/2009 Langan D20/27
D607,941 S * 1/2010 Langan D20/27
D614,703 S * 4/2010 Langan D20/27
D621,879 S * 8/2010 Langan D20/27
D621,880 S * 8/2010 Langan D20/27
D624,595 S * 9/2010 Langan D20/27
D624,596 S * 9/2010 Langan D20/27
D633,151 S * 2/2011 Langan D20/27
D634,367 S * 3/2011 Langan D20/27
D634,368 S * 3/2011 Langan D20/27
D634,369 S * 3/2011 Langan D20/27
D639,861 S * 6/2011 Langan D20/27
D639,862 S * 6/2011 Langan D20/27
D639,863 S * 6/2011 Langan D20/27
D641,421 S * 7/2011 Langan D20/27
D641,422 S * 7/2011 Langan D20/27
D643,468 S * 8/2011 Langan D20/27
D643,469 S * 8/2011 Langan D20/27
D643,470 S * 8/2011 Langan D20/27

D643,471 S * 8/2011 Langan D20/27
D643,472 S * 8/2011 Langan D20/27
D645,094 S * 9/2011 Langan D20/27
D661,742 S * 6/2012 Clark D20/27
D677,732 S * 3/2013 Clark D20/22
8,734,394 B2 * 5/2014 Adams A61M 5/326
604/242
D739,011 S 9/2015 Morrison, Jr. et al.
D773,650 S 12/2016 Fourt et al.
9,872,961 B2 * 1/2018 Fourt A61M 5/2033
10,350,362 B2 * 7/2019 Dennis, Jr. A61M 5/31593
D860,472 S * 9/2019 Blake D24/224
D861,796 S * 10/2019 Hahn D20/27
D898,900 S 10/2020 Atterbury et al.
D905,788 S * 12/2020 Kumar D20/27
11,065,386 B2 * 7/2021 Atterbury A61M 5/2033
D942,544 S * 2/2022 Banh D20/27

FOREIGN PATENT DOCUMENTS

GB 6243008 11/2022
GB 6243009 11/2022
GB 6243010 11/2022
GB 6243011 11/2022
GB 6243158 11/2022

OTHER PUBLICATIONS

Linjawi, S., What Is Trulicity (Dulaglutide) And How Does It Work?, My Health Explained, accessed Jul. 14, 2023 at <https://www.myhealthexplained.com/diabetes-information/diabetes-videos/trulicity-how-do-i-use-it-and-what-does-it-do>, (published Sep. 28, 2021 as indicated by Wayback machine).
Tamble, Mounjaro Weight Loss Online Prescription, accessed Nov. 3, 2023 at <https://www.weightlossmounjaro.net/mounjaro-weight-loss-online-prescription/>.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8